CRISPR Therapeutics Quarterly Balance Sheet
NASDAQ: CRSPHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CRISPR Therapeutics financial position
As of Jun 30, 2026, CRISPR Therapeutics reported total assets of $2.65 billion, up 30.6% from a year earlier against total liabilities of $904.2 million. Shareholders' equity stood at $1.75 billion, or 65.9% of assets. The company held $291.3 million in cash and equivalents against $586.2 million of debt, a net debt position of $294.9 million.
The current ratio (current assets divided by current liabilities) was 17.85, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.34.
Summary generated from market data by MetaCap's automated system. Methodology
CRISPR Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 291.34M | 423.31M | 347.56M | 286.50M | 193.62M | 235.18M | 298.26M | 225.67M | 484.47M | 707.43M | 389.48M | 527.76M |
| Short-Term Investments | 2.07B | 2.02B | 1.63B | 1.63B | 1.53B | 1.62B | 1.61B | 1.71B | 1.52B | 1.40B | 1.30B | 1.21B |
| Receivables | — | — | 0 | 0 | 0 | 0 | 25.00M | 0 | 0 | 0 | 200.00M | — |
| Total Current Assets | 2.37B | 2.45B | 1.99B | 1.93B | 1.73B | 1.87B | 1.94B | 1.94B | 2.01B | 2.12B | 1.91B | 1.76B |
| Property, Plant & Equipment | 108.07M | 112.17M | 115.85M | 120.83M | 124.93M | 129.43M | 134.09M | 138.54M | 143.03M | 147.25M | 151.94M | 156.12M |
| Intangible Assets | — | — | — | — | — | — | 0 | 0 | 0 | 2.00K | 16.00K | 30.00K |
| Long-Term Investments | 0 | 0 | 0 | 28.41M | 0 | 0 | 0 | 0 | 11.22M | 0 | 1.97M | 0 |
| Total Assets | 2.65B | 2.73B | 2.27B | 2.25B | 2.03B | 2.17B | 2.24B | 2.26B | 2.34B | 2.44B | 2.23B | 2.09B |
| Accounts Payable | 11.31M | 13.65M | 11.14M | 11.80M | 9.75M | 13.06M | 14.71M | 15.58M | 9.45M | 16.46M | 38.15M | 26.15M |
| Total Current Liabilities | 132.90M | 136.29M | 149.12M | 118.96M | 104.36M | 119.45M | 87.78M | 89.81M | 127.82M | 118.99M | 108.79M | 111.23M |
| Long-Term Debt | 586.20M | 585.47M | 0 | — | — | — | — | — | — | — | — | — |
| Total Liabilities | 904.22M | 911.26M | 343.43M | 329.33M | 318.59M | 336.94M | 309.95M | 316.47M | 358.90M | 355.08M | 346.77M | 359.04M |
| Shareholders' Equity | 1.75B | 1.81B | 1.92B | 1.92B | 1.71B | 1.83B | 1.93B | 1.94B | 1.98B | 2.08B | 1.88B | 1.73B |
| Retained Earnings | -2.16B | -2.07B | -1.95B | -1.82B | -1.71B | -1.50B | -1.37B | -1.33B | -1.24B | -1.12B | -999.70M | -1.09B |
| Total Debt | 586.20M | 585.47M | 0 | — | — | — | — | — | — | — | — | — |
| Net Cash (Debt) | 1.78B | 1.86B | 1.98B | 1.92B | 1.72B | 1.86B | 1.90B | 1.94B | 2.00B | 2.11B | 1.69B | 1.74B |
| Shares Outstanding | 96.66M | 96.39M | 95.89M | 93.87M | 88.38M | 86.36M | 85.74M | 85.34M | 85.05M | 84.84M | 80.04M | 79.43M |
This table shows 12 quarterly periods of CRISPR Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow CRSP's reporting calendar. What is a balance sheet?